Multiple Myeloma Treatments Drugs
Multiple Myeloma Treatments Drugs - The results of patients with multiple myeloma (MM) treated with conventional chemotherapy with or without high-dose therapy/autologous stem cell transplantation (TCT) was not satisfactory, with an average life expectancy ranging from 2 to 3 years for Older patients. 6 years for younger patients. In recent years, the availability of new effective drugs thalidomide, lenalidomide, and Bortezomib, with new mechanisms of action, has generated real expectations of a significant increase in long-term results. In addition, new drugs targeting new molecular pathways through various mechanisms of action have been developed and are currently being investigated in clinical trials to further improve the results of patients with MM.
Although multiple myeloma still cannot be cured with conventional treatment, the treatment of the disease has recently been altered with the introduction of three new agents, Bortezomib, thalidomide, and Lenalidomide. Bortezomib proteasome inhibitors are approved for the treatment of patients who have received prior therapy; There is growing clinical evidence that shows its own efficacy and in combination with front-line configurations, with high response rates and consistently high response rates.
Multiple Myeloma Treatments Drugs
Multiple Myeloma Treatments Drugs - Thalidomide and Dexamethasone are approved as first-line treatment for multiple myeloma. Other combined schemes, including thalidomide, showed substantial activity in the regulation of relapse and frontline. Recently, thalidomide analogous to Lenalidomide was approved, in combination with dexamethasone, for the treatment of patients who received prior therapy; This scheme showed promising results in the front-line settings. These agents represent a new generation of treatment for multiple myeloma that affects the specific intracellular signaling pathways and the tumor microenvironment. Multiple Myeloma Treatments Drugs - In another novel, targeted therapy is also being evaluated in pre-clinical and clinical studies. The regime combining Bortezomib, thalidomide, Lenalidomide and other new agents, together with commonly used conventional drugs, represents a promising future direction in the treatment of myeloma.
Currently, further investigations are needed to evaluate the security and combination activities that integrate these new agents. However, Bortezomib, thalidomide, and lenalidomide are now widely used clinically. Therefore, this review focuses on the extensive clinical data available from the study of this drug in the treatment of newly diagnosed and advanced multiple myeloma. See also: New Medications for Multiple Myeloma.
Multiple myelomas still cannot be cured with conventional treatment, with an average lifespan of 3-5 years. The disease follows recurrence in most patients, regardless of treatment regimen or initial response to treatment. A new and more effective treatment approach is needed to improve outcomes and prolong survival.
Recently, the administration of multiple myeloma patients was modified by the introduction and approval of three new agents. Bortezomib (Velcade®, Millennium Pharmaceuticals, Inc., Cambridge, MA and Johnson & Johnson Pharmaceuticals Research and Development, LLC, Raritan, NJ) received full approval in 2005 for the care of patients who received at least one therapy Previous Thalidomide (Thalomid®; Celgene Corp, Summit, NJ) in combination with Dexamethasone was approved at the beginning of 2006 for the treatment of newly diagnosed multiple myeloma; and thalidomide analogous to Lenalidomide (REVLIMID®; Celgene Corp., Summit, NJ), also in combination with Dexamethasone, was recently approved for the treatment of patients who received at least one previous therapy.
These three agents represent a new generation therapy for multiple myeloma, which affects the specific intracellular signaling pathways in tumor cells and also targets the tumor microenvironment. Bortezomib is a first-class proteasome inhibitor that has antiproliferative, proapoptotic, antiangiogenic and antitumor activity by inhibiting proteasomal degradation of many regulatory proteins.
Multiple Myeloma Treatments Drugs - In pre-clinical studies, Bortezomib demonstrated the synergistic or additive antitumor activity with agents commonly used in the treatment of multiple myeloma, including doxorubicin, Mellophone and dexamethasone, and activity in myeloma cells that are immune to These agents.
Thalidomide and lenalidomide also show antineoplastic activity in multiple myeloma through various mechanisms of action, including inhibition of angiogenesis, induction of Apoptosis, immunomodulation, antiproliferative effects, inhibition of signaling Cytokines and stimulation of T-cell activity. Preclinical studies have shown that both drugs induce apoptotic cells. Myeloma is resistant to Mellophone, doxorubicin, and dexamethasone and potentializes the activity of dexamethasone and Bortezomib.